 Aytan Musayeva
Concepts (151)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epithelium, Corneal | 6 | 2021 | 10 | 2.650 |
Why?
| | Cornea | 12 | 2023 | 62 | 2.070 |
Why?
| | Corneal Transplantation | 5 | 2023 | 5 | 1.480 |
Why?
| | Visual Acuity | 6 | 2020 | 143 | 1.310 |
Why?
| | Corneal Edema | 3 | 2023 | 4 | 1.310 |
Why?
| | Dry Eye Syndromes | 3 | 2022 | 14 | 1.240 |
Why?
| | Retina | 3 | 2021 | 65 | 1.120 |
Why?
| | Corneal Diseases | 4 | 2023 | 14 | 1.070 |
Why?
| | Endothelium, Corneal | 3 | 2022 | 4 | 1.010 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 2 | 2022 | 2 | 0.990 |
Why?
| | Keratoconus | 1 | 2021 | 4 | 0.840 |
Why?
| | Pentacyclic Triterpenes | 1 | 2021 | 8 | 0.830 |
Why?
| | Goblet Cells | 1 | 2021 | 2 | 0.810 |
Why?
| | Receptor, Muscarinic M3 | 1 | 2021 | 4 | 0.810 |
Why?
| | Protective Agents | 1 | 2021 | 20 | 0.810 |
Why?
| | Conjunctiva | 1 | 2021 | 19 | 0.800 |
Why?
| | Limbus Corneae | 2 | 2020 | 6 | 0.800 |
Why?
| | Fuchs' Endothelial Dystrophy | 1 | 2020 | 2 | 0.770 |
Why?
| | Acanthamoeba Keratitis | 1 | 2020 | 1 | 0.770 |
Why?
| | Eye Infections, Parasitic | 1 | 2020 | 2 | 0.770 |
Why?
| | Reperfusion Injury | 1 | 2021 | 117 | 0.750 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 142 | 0.740 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2018 | 12 | 0.670 |
Why?
| | Tears | 4 | 2022 | 15 | 0.500 |
Why?
| | Cell Proliferation | 1 | 2018 | 1097 | 0.480 |
Why?
| | Mice | 12 | 2023 | 6428 | 0.470 |
Why?
| | Animals | 15 | 2023 | 14402 | 0.430 |
Why?
| | Mice, Inbred C57BL | 6 | 2022 | 2002 | 0.400 |
Why?
| | Arterioles | 3 | 2019 | 35 | 0.400 |
Why?
| | Corneal Opacity | 2 | 2020 | 4 | 0.380 |
Why?
| | Astigmatism | 2 | 2020 | 6 | 0.380 |
Why?
| | Reactive Oxygen Species | 3 | 2021 | 491 | 0.370 |
Why?
| | Mice, Knockout | 4 | 2021 | 928 | 0.360 |
Why?
| | Retrospective Studies | 8 | 2022 | 6462 | 0.350 |
Why?
| | Retinal Diseases | 2 | 2019 | 49 | 0.330 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2019 | 84 | 0.310 |
Why?
| | Vasodilation | 2 | 2019 | 105 | 0.300 |
Why?
| | Aged, 80 and over | 5 | 2020 | 3430 | 0.290 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2389 | 0.280 |
Why?
| | Male | 11 | 2022 | 27335 | 0.260 |
Why?
| | Refraction, Ocular | 2 | 2022 | 9 | 0.250 |
Why?
| | Mustard Gas | 1 | 2023 | 1 | 0.240 |
Why?
| | Corneal Ulcer | 1 | 2023 | 6 | 0.240 |
Why?
| | alpha-MSH | 1 | 2023 | 18 | 0.240 |
Why?
| | Tomography, Optical Coherence | 2 | 2021 | 148 | 0.230 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 1064 | 0.230 |
Why?
| | Cell Count | 2 | 2020 | 181 | 0.230 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 288 | 0.220 |
Why?
| | Corneal Dystrophies, Hereditary | 1 | 2022 | 2 | 0.220 |
Why?
| | Trigeminal Nerve Diseases | 1 | 2022 | 3 | 0.220 |
Why?
| | Tissue Donors | 2 | 2020 | 112 | 0.220 |
Why?
| | Keratitis, Herpetic | 1 | 2022 | 2 | 0.220 |
Why?
| | Corneal Neovascularization | 1 | 2022 | 1 | 0.220 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2022 | 85 | 0.220 |
Why?
| | Keratitis | 1 | 2022 | 17 | 0.220 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2022 | 24 | 0.220 |
Why?
| | Aged | 6 | 2020 | 10054 | 0.210 |
Why?
| | Descemet Membrane | 1 | 2021 | 2 | 0.210 |
Why?
| | Humans | 15 | 2023 | 54304 | 0.210 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2023 | 140 | 0.210 |
Why?
| | Graft vs Host Disease | 1 | 2022 | 84 | 0.210 |
Why?
| | Edema | 1 | 2021 | 74 | 0.200 |
Why?
| | Disease Models, Animal | 3 | 2022 | 1651 | 0.190 |
Why?
| | Corneal Pachymetry | 1 | 2020 | 7 | 0.190 |
Why?
| | Lasers, Excimer | 1 | 2020 | 2 | 0.190 |
Why?
| | Acanthamoeba | 1 | 2020 | 2 | 0.190 |
Why?
| | Benzamidines | 1 | 2020 | 6 | 0.190 |
Why?
| | Antiprotozoal Agents | 1 | 2020 | 10 | 0.190 |
Why?
| | Ophthalmic Solutions | 1 | 2020 | 27 | 0.190 |
Why?
| | Stem Cell Transplantation | 2 | 2021 | 201 | 0.180 |
Why?
| | Retinal Vessels | 1 | 2019 | 13 | 0.180 |
Why?
| | Postoperative Period | 1 | 2020 | 189 | 0.180 |
Why?
| | Hypercholesterolemia | 1 | 2019 | 42 | 0.180 |
Why?
| | Receptor, Muscarinic M1 | 1 | 2019 | 1 | 0.170 |
Why?
| | Middle Aged | 5 | 2020 | 13076 | 0.170 |
Why?
| | Retinal Artery | 1 | 2019 | 5 | 0.170 |
Why?
| | Apolipoproteins E | 1 | 2019 | 62 | 0.170 |
Why?
| | Intraocular Pressure | 1 | 2019 | 89 | 0.170 |
Why?
| | Retinal Ganglion Cells | 1 | 2019 | 23 | 0.170 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 426 | 0.170 |
Why?
| | Adult | 5 | 2020 | 14189 | 0.170 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2018 | 87 | 0.160 |
Why?
| | RNA, Messenger | 2 | 2019 | 1203 | 0.160 |
Why?
| | Norepinephrine | 1 | 2018 | 119 | 0.160 |
Why?
| | Ophthalmic Artery | 1 | 2017 | 3 | 0.160 |
Why?
| | Female | 8 | 2023 | 28457 | 0.160 |
Why?
| | Antifungal Agents | 1 | 2020 | 363 | 0.150 |
Why?
| | Vasodilator Agents | 1 | 2017 | 111 | 0.140 |
Why?
| | Regeneration | 1 | 2017 | 72 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 1476 | 0.140 |
Why?
| | Postoperative Complications | 1 | 2021 | 1035 | 0.120 |
Why?
| | Oxidative Stress | 1 | 2019 | 956 | 0.120 |
Why?
| | Aging | 1 | 2019 | 782 | 0.110 |
Why?
| | Mice, Inbred BALB C | 2 | 2023 | 371 | 0.110 |
Why?
| | Signal Transduction | 1 | 2018 | 1751 | 0.100 |
Why?
| | Corneal Topography | 2 | 2020 | 6 | 0.100 |
Why?
| | Young Adult | 1 | 2020 | 4313 | 0.090 |
Why?
| | Tissue Preservation | 1 | 2023 | 9 | 0.060 |
Why?
| | Mechlorethamine | 1 | 2023 | 4 | 0.060 |
Why?
| | Neutrophil Infiltration | 1 | 2023 | 29 | 0.060 |
Why?
| | Cytoprotection | 1 | 2023 | 48 | 0.060 |
Why?
| | Antigen-Presenting Cells | 1 | 2023 | 25 | 0.060 |
Why?
| | Streptozocin | 1 | 2023 | 27 | 0.060 |
Why?
| | Microscopy, Confocal | 1 | 2023 | 110 | 0.060 |
Why?
| | Vision Disorders | 1 | 2023 | 74 | 0.060 |
Why?
| | Monocytes | 1 | 2023 | 156 | 0.060 |
Why?
| | Fluorescein | 1 | 2022 | 9 | 0.050 |
Why?
| | Eye Pain | 1 | 2022 | 6 | 0.050 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2022 | 12 | 0.050 |
Why?
| | Trigeminal Ganglion | 1 | 2022 | 2 | 0.050 |
Why?
| | Substance P | 1 | 2022 | 26 | 0.050 |
Why?
| | Sensory Receptor Cells | 1 | 2022 | 14 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2022 | 106 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2022 | 195 | 0.050 |
Why?
| | Wound Healing | 1 | 2023 | 228 | 0.050 |
Why?
| | Graft Rejection | 1 | 2022 | 161 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2023 | 294 | 0.050 |
Why?
| | Photorefractive Keratectomy | 1 | 2020 | 1 | 0.050 |
Why?
| | Re-Epithelialization | 1 | 2020 | 1 | 0.050 |
Why?
| | Macrophages | 1 | 2023 | 404 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2020 | 17 | 0.050 |
Why?
| | Cell Line | 1 | 2023 | 1152 | 0.050 |
Why?
| | Prednisolone | 1 | 2020 | 57 | 0.050 |
Why?
| | Hypertrophy | 1 | 2020 | 55 | 0.050 |
Why?
| | Stem Cells | 1 | 2021 | 194 | 0.050 |
Why?
| | Perfusion | 1 | 2019 | 41 | 0.050 |
Why?
| | Cadaver | 1 | 2020 | 113 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 60 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2021 | 255 | 0.040 |
Why?
| | Gene Expression | 1 | 2022 | 664 | 0.040 |
Why?
| | Eye Proteins | 1 | 2019 | 19 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2019 | 62 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2019 | 233 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 383 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 248 | 0.040 |
Why?
| | RNA | 1 | 2019 | 202 | 0.040 |
Why?
| | Acetylcholine | 1 | 2017 | 53 | 0.040 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2017 | 26 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2019 | 205 | 0.040 |
Why?
| | Potassium Channels | 1 | 2017 | 41 | 0.040 |
Why?
| | Catalase | 1 | 2017 | 74 | 0.040 |
Why?
| | Cell Survival | 1 | 2019 | 657 | 0.040 |
Why?
| | Blood Pressure | 1 | 2019 | 586 | 0.040 |
Why?
| | Cytokines | 1 | 2019 | 677 | 0.040 |
Why?
| | Pregnancy | 1 | 2023 | 2637 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2017 | 298 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 1693 | 0.030 |
Why?
| | Risk Factors | 1 | 2022 | 3934 | 0.030 |
Why?
| | Models, Biological | 1 | 2017 | 825 | 0.030 |
Why?
| | Time Factors | 1 | 2019 | 3207 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2020 | 5609 | 0.020 |
Why?
|
|
Musayeva's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
|